Adia Med Inc

What they do

ADIA Nutrition operates through its acquisition of Biolete LLC, offering medical procedures, biologics, and dietary supplements. The company's revenue mix is dominated by medical procedures and sales of biologics, with supplements and shipping/delivery services as smaller components.

Revenue drivers

• Medical procedures — Largest revenue source; for Q2 2026, generated $329,820 (68.0% of quarterly revenue) and $434,670 (65.7% of six-month revenue).
• Sales of biologics — Second-largest segment; Q2 2026 revenue of $151,750 (31.2% of quarterly revenue) and $221,525 (33.5% of six-month revenue).
• Sales of supplements — Minimal contributor; no supplement revenue in H1 2026, down from $2,155 in H1 2025 (1.1% of revenue).
• Shipping and delivery — Small ancillary revenue; $3,815 in Q2 2026 and $5,465 for H1 2026 (0.8% of revenue).

Recent performance

For the six months ended June 30, 2026, revenue rose to $661,660 from $189,910 in the prior-year period, with gross profit improving to $350,157 from $39,975. Q2 2026 revenue was $485,385, up sharply from $118,146 in Q2 2025. Despite revenue growth, the company reported a net loss of $395,464 for fiscal 2025 and has an accumulated deficit, with negative shareholder equity of $-379,781 as of June 30, 2026. Operating cash flow was negative in both fiscal 2024 ($-335,476) and 2025 ($-179,228). Total liabilities of $1.1M exceeded total assets of $744,054 as of June 30, 2026.

Strategy

The company is executing on its post-shell business model, focusing on medical procedures and biologics sales, which drove significant revenue growth in H1 2026 compared to H1 2025. It is incurring operating expenses in legal/professional fees, advertising, and salaries to support expansion. Management is also extending a loan to a start-up facility, generating interest income, suggesting investment in external operations. The company is prioritizing revenue scale while managing high cost of revenue, particularly for biologics and medical procedures.

Risks

• Negative equity — Shareholder equity was $-379,781 as of June 30, 2026, indicating accumulated losses and a weak balance sheet.
• Liquidity constraint — Cash and equivalents were only $128,115 with total liabilities of $1.1M, and operating cash flows were negative in both fiscal 2024 and 2025.
• Dependence on related-party financing — The company incurs interest expenses on a line of credit facility with a related party, highlighting reliance on insider funding.
• Competitive pressure — The company faces competition from companies with more established or more effective products, which could impair its ability to generate revenue.

Outlook

Management expects to continue growing revenue through its medical procedures and biologics segments, as evidenced by the significant year-over-year increase in H1 2026. The company is investing in clinical trial fees and public relations, suggesting an intent to validate and market its offerings. However, no specific forward guidance is provided beyond the risk factors cautioning about uncertain execution and funding needs.